Clinical Trials
18 trialsNCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT03425279 2025-09-23
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
BioAtla, Inc.
Phase 1/2 Completed
NCT04242238 2025-08-28
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02584309 2023-11-07
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT03009201 2023-08-16
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 1 Completed
NCT00346164 2022-04-28
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT03381846 2020-08-05
Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger
Mayo Clinic
Phase NA Completed
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT01154452 2018-08-15
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00659360 2018-06-29
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01653028 2017-11-30
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00720174 2016-05-17
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00474994 2016-01-20
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00084630 2013-02-28
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
National Cancer Institute (NCI)
Phase 2 Completed
NCT00243191 2012-03-29
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00122473 2011-07-29
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
Dermatologic Cooperative Oncology Group
Phase 1/2 Completed